Codon

AUGUST 4, 2025

Today, it is used in everything from chemical analysis to drug discovery, but it was not initially developed with biologists in mind. A small molecule “barcode” is added to each droplet and attaches itself to the proteins within. Credit: PTI Next, these protein-filled droplets are studied using mass spectrometry.

Laboratories

New Drug Approvals

JULY 28, 2025

1] Unlike other diabetes drugs, it is intended to increase insulin sensitivity. [2] 133 This first-in-class, small molecule,oral,glucokinaseactivator(GKA)wasfirst approved in ChinainSeptember2022foradultpatientswithT2DMasa monotherapy and in combination with metformin (an antidiabetic medication).134 Drugs 2022, 82, 1745−1750.

Small Molecule

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule

Metabolite Tales Blog

APRIL 10, 2024

Where data was publicly available, the routes of human metabolism for each of the drugs in this subset is listed in Table 1. Metabolites found in humans are also observed in monkeys, and all metabolites were found to possess <10% of the activity of the parent drug. of the administered radiolabel in the human ADME study.

Small Molecule

Metabolite Tales Blog

JANUARY 26, 2023

Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism.

Small Molecule

Metabolite Tales Blog

APRIL 4, 2023

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4.

Small Molecule

Metabolite Tales Blog

JANUARY 23, 2024

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. Enzymes involved include CYP1A2, CYP2C8, CYP3A4, CYP4F2, and aldehyde oxidase (AOX).

Small Molecule

Broad Institute

OCTOBER 4, 2023

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule

Tebu Bio: Drug Discovery

MARCH 27, 2020

“A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing” (March 2020) bioRxiv). For example, a recent study has identified 332 high confidence SARS-CoV-2-human protein-protein interactions (Gordon D.E. All these efforts are […]

Small Molecule

Drug Target Review

MARCH 28, 2024

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. This can allow researchers to routinely uncover about 10,000 distinct molecules per plant sample, each of which has the potential to interact with human biology and inspire new medicines.

Production

The Pharma Data

JANUARY 19, 2021

Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. About ALS-4.

Small Molecule

Drug Target Review

SEPTEMBER 25, 2024

While these approaches often produce encouraging initial results, the development of drug resistance remains a major obstacle for long-term patient survival. Classically, rational drug combinations are designed to target two nodes in the same oncogenic signalling pathway.

Small Molecule

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. The program was initiated in April 2020. About Sosei Heptares.

Small Molecule

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. Conference Call Information : Date : Thursday, November 5, 2020. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. WALTHAM, Mass.,

Pharmaceuticals

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Chief Executive Officer of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule

LifeSciVC

JANUARY 16, 2024

Small molecule GLP1s? Whether trial design, execution, or otherwise, drug development even where there is precedent is a challenging road and should not be taken for granted. Whether it’s small molecules to target the incretins (GLP1R ± GIPR), targeting well-validated signaling nodes in I&I (e.g.,

Small Molecule

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease

The Pharma Data

DECEMBER 20, 2020

21, 2020 11:00 UTC. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented: “Further to our previous update in September 2020, we are pleased to announce this CTA submission which represents a major development milestone for our ALS-4 antimicrobial program. About ALS-4.

Small Molecule

FDA Law Blog: Biosimilars

JULY 11, 2023

Koblitz — One of the most important questions FDA has to answer is whether a given product is appropriately characterized as a drug, biologic, device, food, cosmetic, or something entirely different. the nanotube—is irrelevant, as it is the “active ingredient” that matters for purposes of classifying the product as a drug or biologic.

FDA

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. Adagrasib is an investigational small molecule and selective KRAS G12C inhibitor in clinical development as a monotherapy and in combinations. SAN DIEGO , Oct.

Small Molecule

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA

Drug Target Review

NOVEMBER 1, 2023

3 Another recent development is the implication of ATX in neurological diseases, 6,7 as ATX levels are related to metabolic disorders in Alzheimer disease, and thus might be an interesting biomarker and drug target for this devasting pathology. 2020 Jan 1;57(1):372–92. He is a researcher at University of Oldenburg, Germany. J Med Chem.

Clinical Trials

The Pharma Data

NOVEMBER 29, 2020

30, 2020 07:00 UTC. Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ? TOKYO & CAMBRIDGE, England–( BUSINESS WIRE )– Eisai Co., please visit [link].

Small Molecule

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. LEXINGTON, Mass.–(

Pharmaceuticals

The Pharma Data

NOVEMBER 22, 2020

23, 2020 13:30 UTC. SAN DIEGO–( BUSINESS WIRE )– Vividion Therapeutics , a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.

Small Molecule

The Pharma Data

FEBRUARY 4, 2021

3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. AbbVie hosted an Immunology Strategic Update event on December 14, 2020 for members of the investment community. NORTH CHICAGO, Ill., Gonzalez , chairman and chief executive officer, AbbVie.

Production

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. SAN JOSE, Calif. ,

Pharmaceuticals

Drug Target Review

MAY 23, 2023

Micro- and macroalgae from both marine and fresh water produce small molecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and small molecules like terpenoids and peptides, found in microalgae.

Drugs

The Pharma Data

DECEMBER 23, 2020

LYT-100 is an anti-fibrotic and anti-inflammatory oral small molecule that has been designed to overcome the tolerability challenges associated with pirfenidone, an anti-inflammatory, anti-fibrotic drug currently on the market. Chen, told BioSpace that the company expects results in the second half of 2021. said in a statement.

Clinical Trials

Drug Target Review

JUNE 12, 2023

This molecule shows immense potential as a pan-TEAD inhibitor, targeting advanced solid tumours. TEAD proteins are crucial for tumour progression and drug resistance, making them an attractive focus for therapeutic interventions. How was ISM6331 generated and optimised using Chemistry42?

Metabolic Stability

Drug Target Review

JANUARY 5, 2024

fowleri cases 3 suggest that combinations of antibiotic and antifungal drugs, including azithromycin, amphotericin B, fluconazole, rifampin and miltefosine (the latter originally formulated for leishmaniasis and cancer chemotherapy 4 ), have a minimal impact on survival. Recent reviews of N.

Small Molecule

Molecular Design

AUGUST 9, 2020

> I sometimes wonder what percentage of the pharmacopoeia will have been proposed for repurposing for the treatment of COVID19 by the end of 2020. Those attempting to use text mining and machine learning to prioritize drugs for repurposing should take note of the views expressed in this tweet.

Drugs

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS ® small molecule nanoparticle technology non-GMP lines. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! HELSINKI , Nov.

Small Molecule

The Pharma Data

OCTOBER 27, 2021

Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. With the introduction of small-molecule medication, we open a new chapter in the fight against neurodegenerative diseases and have the chance to improve the lives of millions of patients drastically.”.

Licensing

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine

The Pharma Data

DECEMBER 15, 2020

16, 2020 14:00 UTC. Validated technology platform translates novel molecules from plants into first-in-class medicines. These chemicals are then further optimized in laboratory studies by Enveda’s team of biologists and medicinal chemists to deliver validated first-in-class drug candidates. and Enveda’s founding CEO.

Small Molecule

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Preclinical data show SLV213 is a potent inhibitor of SARS-CoV-2 infection. About SLV213.

Treatment